This is a $3,562,513 cost-plus-fixed-fee definitive contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to Altasciences Clinical Kansas Inc. The contract is for pharmacokinetic and pharmacodynamic studies to support the development of medications for substance use disorders. The contract period of performance is from September 20, 2017 to September 19, 2022, with an ultimate completion date of July 31, 2025. This award is not associated with any set-aside. Altasciences Clinical Kansas Inc. is a for-profit contract research organization that specializes in early-phase drug development services. The purpose of this contract is to provide clinical pharmacology research services to support NIDA's mission of advancing treatments for substance use disorders.
Generated 8/1/24, 10:03 AM